(Q47898513)

6 February 2018

title

Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. (English)

1 reference

6 February 2018

author name string

Scott B Halstead

series ordinal

1

1 reference

6 February 2018

language of work or name

English

0 references

publication date

10 October 2017

1 reference

6 February 2018

number of pages

4

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

6 February 2018

volume

35

1 reference

6 February 2018

page(s)

6355-6358

1 reference

6 February 2018

issue

47

1 reference

6 February 2018

Dengue vaccine safety signal: Immune enhancement, waning immunity, or chance occurrence?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Efficacy of a tetravalent dengue vaccine in children in Latin America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Protective and immunological behavior of chimeric yellow fever dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

A Protective Role for Dengue Virus-Specific CD8+ T Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

T-cell immunity to infection with dengue virus in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Human CD8+ T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Patterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

Epidemiologic studies on Dengue in Santiago de Cuba, 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.089

10.1016/J.VACCINE.2017.09.089

7 January 2021

Identifiers

DOI

1 reference

6 February 2018

PubMed ID

29029938

1 reference

6 February 2018